Ionis Pharmaceuticals IONS AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's afs and trading securities - unrealized loss position (<12 months) accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) accumulated loss?
- Ionis Pharmaceuticals (IONS) reported AFS and trading securities - unrealized loss position (<12 months) accumulated loss of 368 in Q1 2026.
- How has Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) accumulated loss changed year-over-year?
- Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) accumulated loss increased by 17.9% year-over-year, from 312 to 368.
- What does AFS and trading securities - unrealized loss position (<12 months) accumulated loss mean?
- The total temporary paper losses on short-term investment holdings held for less than a year.
- How do you interpret AFS and trading securities - unrealized loss position (<12 months) accumulated loss?
- An increase suggests rising interest rates or market volatility affecting the company's short-term investment portfolio.
- How does AFS and trading securities - unrealized loss position (<12 months) accumulated loss compare across companies?
- Commonly reported by biotech firms with significant cash reserves invested in fixed-income securities.